نتائج البحث

1

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

المؤلفون: Jianying Zhou, Caicun Zhou, Zhehai Wang, Chengping Hu, Wen Zhang, Dingzhi Huang, Lianke Liu, H. Zhao, Shundong Cang, Jianxin Xue, Chengzhi Zhou, Jian Fang, Li Zhang, Gongyan Chen, Zhixiong Yang, Ping Sun, Min Fan, Hui Zhou, Juan Li, Jiuwei Cui, Lin Wu, Baolan Li, Yingying Du, Yun Fan, Yuping Li, Shuyan Wang

المصدر: Journal of Thoracic Oncology. 16:1501-1511

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ae08ff7166f291e1979183f19d3e976cTest
https://doi.org/10.1016/j.jtho.2021.04.011Test

2

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

المؤلفون: Weiqiang Chen, Xiuwen Wang, Kejun Nan, Li Zhang, Jianxing He, Baohui Han, Jing Zhu, Zhehai Wang, Kai Li, Baolan Li, Faguang Jin, Qiming Wang, Yi Luo, Ying Cheng, Jianhua Shi, Yuankai Shi

المصدر: Cancer Medicine, Vol 9, Iss 8, Pp 2621-2630 (2020)
Cancer Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c71178d0f1b1011129c0a59a412f98Test
https://doaj.org/article/d4fedd9759804f7bb2adee9ef4881b82Test

3

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

المؤلفون: Christoph Mancao, Yong Song, Weimin Li, Jifeng Feng, Jian Fang, Wenfeng Fang, Bo Peng, Zhixiong Yang, Shundong Cang, Qitao Yu, Zhehai Wang, Hui Zhou, Jianying Zhou, Gongyan Chen, Juan Li, Xiaodong Mei, Luyao Sun, Jiya Sun, Oscar Puig, Li Zhang, Shuyan Wang, Rui Zhou, Rui Ma, Xiubao Ren, M. Bi, You Lu, Baohui Han, Yunpeng Yang, Zhiyong He, Wei Xu, Baolan Li

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(12)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de7ce8bbbf8321308b8a04bc581ada8cTest
https://pubmed.ncbi.nlm.nih.gov/34358724Test

4

Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer

المؤلفون: Zhehai Wang, Yi Luo, Kai Li, Weiqiang Chen, Baolan Li, Yinlan Chen, Yin Cheng, Xiaoyan Si, Hanping Wang, Faguang Jin, Jianhua Shi, Jianying Zhou, Xiuwen Wang, Xiaotong Zhang, Li Zhang, Donglin Wang, Jianxing He, Mengzhao Wang, Kejun Nan, Yuankai Shi, Baohui Han, Qiming Wang

المصدر: Lung Cancer. 122:32-37

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Indoles, Lung Neoplasms, Constipation, medicine.medical_treatment, Antineoplastic Agents, Placebo, Targeted therapy, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Quality of life, Carcinoma, Non-Small-Cell Lung, Surveys and Questionnaires, Internal medicine, medicine, Humans, Lung cancer, Aged, Neoplasm Staging, Chemotherapy, business.industry, Cancer, Middle Aged, Placebo Effect, medicine.disease, Survival Analysis, humanities, Clinical trial, Treatment Outcome, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Quality of Life, Quinolines, Female, medicine.symptom, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::366fa91fcfbcbe6f96bd4465e39033d1Test
https://doi.org/10.1016/j.lungcan.2018.05.013Test

5

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

المؤلفون: You Lu, Conghua Xie, Zhehai Wang, Xiaodong Mei, Baohui Han, Zhixiong Yang, Donglei Zhu, Jianying Zhou, M. Bi, Baolan Li, Lijun Wang, Wen Zhang, Nong Yang, Yunpeng Yang, Yong Song, Weimin Li, Zhiyong He, Ying Cheng, Shuyan Wang, Rui Ma, Juan Li, Zhuang Yu, Xiubao Ren, Yan Zhang, Qitao Yu, Jian Fang, Jifeng Feng, Rui Zhou, Yanqiu Zhao, Li Zhang, Hui Zhou, Shundong Cang, Gongyan Chen, Yingyi Wang

المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(10)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99d8e9dc5d07cd3f270abd0b55d3e84Test
https://pubmed.ncbi.nlm.nih.gov/33246599Test

6

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

المؤلفون: Yizhuo Zhao, Kai Li, Jianying Zhou, Baolan Li, Yi Luo, Zhehai Wang, Ying Cheng, You Lu, Guoming Wu, Liyan Jiang, Yuankai Shi, Cheng Huang, Qiang Li, Baohui Han, Yiping Zhang

المصدر: British Journal of Cancer

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, China, Indoles, Lung Neoplasms, Population, Placebo, Gastroenterology, Drug Administration Schedule, law.invention, 03 medical and health sciences, Young Adult, 0302 clinical medicine, tyrosine kinase inhibitor, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Carcinoma, Non-Small-Cell Lung, Medicine, Humans, anlotinib, Progression-free survival, multitarget, Lung cancer, education, Adverse effect, Protein Kinase Inhibitors, third line, Aged, education.field_of_study, business.industry, Hazard ratio, Middle Aged, medicine.disease, Progression-Free Survival, Clinical trial, 030104 developmental biology, Treatment Outcome, Oncology, non-small-cell lung cancer, 030220 oncology & carcinogenesis, Quinolines, Clinical Study, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d393c1e6811876e98c4b2ad30941282Test
https://pubmed.ncbi.nlm.nih.gov/29438373Test

7

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

المؤلفون: Ying Cheng, Yizhuo Zhao, Kai Li, Qiming Wang, Zhehai Wang, Baolan Li, Jian Dong, Kejun Nan, Jianxing He, Robert Pirker, Weiqiang Chen, Xiuwen Wang, Baohui Han, Li Zhang, Hao Yu, Yang Zhao, Yuankai Shi, Lin Wu, Faguang Jin, Yan Sun, Yi Luo, Jianhua Shi

المصدر: JAMA Oncol

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::471c7bacc2c620382fefe525a2142362Test
https://doi.org/10.1001/jamaoncol.2018.3039Test

8

Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect

المؤلفون: Yuankai Shi, Qiming Wang, Weiqiang Chen, Yi Luo, Zhehai Wang, Jianxing He, Kejun Nan, Faguang Jin, Li Zhang, Jianhua Shi, Kai Li, Baolan Li, Ying Cheng, Baohui Han, Xiuwen Wang

المصدر: Journal of Clinical Oncology. 36:e21182-e21182

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Subgroup analysis, Placebo, Double blind, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Refractory, 030220 oncology & carcinogenesis, Internal medicine, Medicine, In patient, Anlotinib Hydrochloride, business, neoplasms

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::65c4ff1c7bb44c399628fe58a10ed006Test
https://doi.org/10.1200/jco.2018.36.15_suppl.e21182Test

9

Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study

المؤلفون: Jianying Zhou, Xiuwen Wang, Yin Cheng, Jianhua Shi, Li Zhang, Donglin Wang, Qiming Wang, Weiqiang Chen, Yi Luo, Yuankai Shi, Zhehai Wang, Kejun Nan, Faguang Jin, Yinlan Chen, Baohui Han, Yizhuo Zhao, Kai Li, Jianxing He, Baolan Li

المصدر: The Lancet Oncology. 18:S3

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::626b61c5aaebac2a29e9e929aa780ce9Test
https://doi.org/10.1016/s1470-2045Test(17)30759-3

10

Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study—Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC

المؤلفون: Xiuwen Wang, Yuankai Shi, Baihui Han, Jianhua Shi, Yinglan Chen, Zhehai Wang, Li Zhang, Yi Luo, Ying Cheng, Donglin Wang, Jianxing He, Weiqiang Chen, Yizhuo Zhao, Kai Li, Baolan Li, Kejun Nan, Faguang Jin, Jianying Zhou, Qiming Wang

المصدر: Journal of Clinical Oncology. 35:9053-9053

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4735cd60806942150a99c5276db9ce02Test
https://doi.org/10.1200/jco.2017.35.15_suppl.9053Test

تنقيح النتائج